[ad_1]
Five months after emergency use … WHO solidarity study results disappointing, effects remain controversial
Remdesivir is officially approved for use by the US health authorities, making it the first and only official corona treatment available to all corona patients.
The United States Food and Drug Administration (FDA) officially authorized remdesivir from Gilead Sciences, a global pharmaceutical company in the United States, for use in the treatment of hospitalized patients with COVID-19 on the 22nd (local time) . Previously, the FDA approved remdesivir for “emergency use” in May, but five months later, it was “formally approved” as a corona treatment. Daniel O’Day, CEO of Gilead Sciences, said: “After the Corona 19 pandemic started, we worked hard to solve it, and it hasn’t been a year since we got FDA approval and I can’t believe it.”
Although remdesivir was originally developed as a treatment for Ebola, it was found to have been effective in hospitalized patients after the coronavirus pandemic around the world earlier this year. According to results of clinical trials conducted earlier this month, conducted at 73 medical institutions in 10 countries and 10 countries led by the National Institutes of Health, the recovery period for severely hospitalized patients who received treatment was shortened by 5 days. 15 days to 11 days compared to those who received placebo. Appear.
Consequently, everyone started importing remdesivir. It is also reported that US President Donald Trump, who was infected with Corona 19 last month, received remdesivir along with other medications. Korea also approved special imports from health authorities in June and supplied them to Korea, with 600 patients with severe corona19 reported to have been administered as of 13 this month.
Although Remdevicir was found to reduce the ‘recovery period’ for severely hospitalized patients, no statistical significance was found in reducing the ‘death rate’. Also, it was found to have no effect in patients with mild symptoms. A recent joint study by the World Health Organization (WHO) showed that remdesivir failed to reduce the mortality rate and length of hospitalization, generating controversy about the effect of treatment.
The WHO solidarity study is that scientists and hospitals in more than 30 countries around the world participated in the same research protocol in the absence of an approved treatment for Corona 19. It has tested the effects of remdesevir, which until now is known which has antiviral effects on the coronavirus, as well as chloroquine, kaletra, and interferon.
Kim Woo-joo, professor of infectious medicine at Daeguro Hospital in Korea, who has served as president of the Korean Association for Infectious Diseases in connection with the WHO solidarity study, said: “It is not only possible to have an effect positive once in a clinical trial, but can only be trusted if it is published continuously. Hope and disappointment intersect in the absence of a well-proven treatment, but in any case, it is hopeful that many scientists around the world world are going through the same research protocol to demonstrate the efficacy of the drug in the crown crisis. “
Copyright owner © Doctor Shinmun Unauthorized reproduction and redistribution prohibited
